Patients with cancer should receive a tailored exercise prescription to protect their heart, reports a paper published today (October 6, 2019) in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology (ESC).1
‘Cancer patients are often less active than adults without cancer,’ said author Dr Flavio D’Ascenzi, University of Siena, Italy. ‘However, exercise is essential for patients diagnosed with cancer who are under treatment, irrespective of the type of treatment.’
‘Endurance training is more effective for improving cardiovascular performance and reducing inflammation, but resistance training may be a better starting point for frail cancer patients,’ he continued. ‘Other types of exercise, such as inspiratory muscle training, are safe and effective, particularly in those with thoracic cancer; therefore, the specific exercise should be chosen based on individual characteristics.’
Cardiovascular diseases are common side effects in patients with cancer. This is the result of cardiotoxicity, whereby cancer treatment impairs heart function and structure, or accelerated development of cardiovascular disease, especially when risk factors such as high blood pressure are present. Furthermore, cardiovascular diseases and cancer often share the same risk factors. Therefore, cancer patients are advised to eat healthily, quit smoking, control their weight, and exercise.2
Today’s paper highlights the importance of an individual exercise plan for each patient, taking into account personal history, cancer treatment, response to exercise, and personal preferences. Exercise should start as soon as possible, even before starting treatment such as chemotherapy.
A multidisciplinary team should be involved in formulating an exercise prescription, including oncologists, cardiologists, physical therapists, nurses, nutritionists, and psychologists. Cardiac evaluation, with exercise testing (and particularly cardiopulmonary exercise testing or lactate testing) to determine response to exercise, is the starting point. The appropriate ‘dose’ of exercise (as usually done for a drug) can then be prescribed, including the intensity, type of training, and training volume (hours/minutes of training per week).
‘Defining the intensity and volume of exercise is important for maximizing the benefits of physical activity while avoiding muscular soreness, fatigue, and sleep disorders,’ said Dr D’Ascenzi.
Ongoing treatment is not a contraindication to exercise, but patients are urged to consult their doctor before starting a new activity. Specific guidance is provided: for example, patients with low hemoglobin levels should avoid high-intensity activities; those with low platelet levels (needed for blood clotting) should not do contact sports. Activities that could increase the risk of fracture should be avoided in frail patients. Breathlessness or fatigue must be investigated but, after excluding associated health problems, exercise can help cope with fatigue, which is relatively common in cancer patients.
Dr D’Ascenzi concluded: ‘Physical activity before, during and after cancer treatment can counteract the negative effects of therapies on the cardiovascular system. In addition, it can relieve symptoms such as nausea and fatigue and help prevent unwanted changes in body weight.’
1. “The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology” by Flavio D’Ascenzi, Francesca Anselmi, Caterina Fiorentini, Roberta Mannucci, Marco Bonifazi and Sergio Mondillo, 6 October 2019, European Journal of Preventive Cardiology.
2. “2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)” by Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J Lenihan, Gregory Y H Lip, Alexander R Lyon, Teresa Lopez Fernandez, Dania Mohty, Massimo F Piepoli, Juan Tamargo, Adam Torbicki, Thomas M Suter and ESC Scientific Document Group, 21 September 2016, European Heart Journal.